SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : VOLTAIRE'S PORCH-MODERATED -- Ignore unavailable to you. Want to Upgrade?


To: Dalin who wrote (46253)1/12/2002 5:08:43 PM
From: Sully-  Read Replies (2) | Respond to of 65232
 
Are these forces allowed to go into combat naked from the neck down?

:-\



To: Dalin who wrote (46253)1/12/2002 6:16:55 PM
From: stockman_scott  Respond to of 65232
 
An excerpt from this morning's Barrons Roundtable discussion:

Q: In that case, let's move on to stock-picking. Barton, you're up.
Biggs: The bear market is 75%-80% over. The September lows were very important. I think we're going to go back and test them at some point this year. I hope to hell they hold.

Q: And if they don't?
Biggs: Then we are in a secular bear market. Mutual funds will get a cascading round of redemptions. But I don't think that is going to happen. Anyway, things have gotten crazy again. We have gone back to being underweight equities and overweight bonds. We are very underweight tech. They are blowing up the same bubble that existed before. Our big concentrations are in growth stocks. This is a slow-growth, low-inflation world, and growth stocks are going to do great in that environment. They are going to sell at very high P/E ratios. I think the biotech sector is going to be the next bubble, because it has all the right characteristics of dreamability. It has no earnings. No analyst can possibly understand these stocks and really be of added value.

Q: Would you short them?
Biggs: Gosh, no, not at this point. The bubble has not been blown up yet. Look at the technical pattern of the biotechs. They have bounced off a big, long bottom that was put in place since the 1990s. There are going to be some great stocks here. People tell me there is a great story in Regeneron, which has a drug that makes you lose weight and keep it off. But you really have to buy the broad-exposure companies like Genentech.

Q: How long do you think the bubble will last?
Biggs: Maybe 18 months. We have a major overweight in U.S. healthcare again. I am not a believer in PEG [price to earnings growth] ratios, but the drug companies are not going to grow as fast as people think they are. There is going to be tremendous price pressure. The big drug companies aren't going to grow 12%, 13%, 14% a year, but they are going to grow 7% or 8% or 10% a year. I think they will sell at 1950s and '60s-type P/E ratios on that kind of growth. So Bristol-Myers Squibb, American Home Products, Abbott Laboratories, Schering-Plough, and in Europe, Novartis, make sense to me.
Schafer: One thing that will keep the biotech bubble going is that the big drug companies, which heretofore merged with each other, are now buying biotech companies. That is their only area of growth.



To: Dalin who wrote (46253)1/13/2002 3:43:09 PM
From: stockman_scott  Read Replies (1) | Respond to of 65232
 
Accounting Fraud Rising

money.cnn.com

Accounting fraud rising
January 11, 2002: 4:05 p.m. ET

Enron is simply the latest case as accountants face increasing client pressure.

By Staff Writer John Chartier

NEW YORK (CNN/Money) - As details unfold about the accounting shenanigans that led to Enron's collapse, federal regulators note the case is simply the latest in a growing string of high profile scandals at major U.S. corporations in recent years.

The number of fraud cases investigated by the Securities and Exchange Commission jumped 41 percent in the last three years, according to agency data, resulting in tens of millions of dollars in fines to settle the charges.

Regulators said such cases are becoming all too common in an increasingly cutthroat atmosphere where client pressure to make sure the numbers add up often leads to ethical breaches.

"Accountants don't have that sensitivity. They don't have the sense that numbers hurt," said one former corporate accountant who asked not to be identified. "Early on in their career they learn to shave the truth."

Before Enron (ENE: unchanged at $0.67, Research, Estimates) slid into bankruptcy, wiping out the retirement savings of many of its employees, several high-profile companies attracted SEC interest, and ultimately paid fines, to settle accounting charges. Waste Management (WM: down $0.38 to $34.64, Research, Estimates) , Cendant (CD: down $0.09 to $19.15, Research, Estimates) , Sunbeam and MicroStrategy (MSTR: up $0.21 to $4.09, Research, Estimates) all faced federal scrutiny.

Pressure from clients on their accountants to make the numbers add up is so great that accountants are faced with a dilemma when there's a problem, betray the client, or overlook it, hoping no one notices and risk getting caught, industry watchers said.

Much of the pressure brought to bear on accountants stems from the cozy relationships the firms have with corporate clients. Corporations often hire accountants and other personnel from their auditors and accountants, regulators said.

That's what happened in Waste Management's case.

"I think for all the relevant periods, the chief accounting officers at Waste Management came from Arthur Andersen," said one SEC regulator. "The relationship is too cozy."

Statistics appear to support the idea that companies are increasingly trying to get away with cooking the books. According to SEC data, regulators investigated 112 cases in 2001. That's a 41 percent increase from the 79 cases investigated in 1998.

"There are more financial misstatements and fraud now," SEC spokesman Thomas Newkirk said. "There was a time it was a rare day to get caught in a fraud case. In the last year or two lots of big capitalization, nationally known companies have been involved in financial fraud."

The list keeps growing

Andersen, which admitted late Thursday to destroying Enron-related documents, was fined $7 million in June, the biggest civil penalty ever assessed against a Big Five accounting firm, after the SEC said its audits of Waste Management's financial statements were "false and misleading."

The SEC said the company failed to stand up to the biggest U.S. trash hauler to prevent accounting irregularities.

In November, Waste Management itself paid $457 million in fines to settle charges of violating securities laws in its 1998 merger with USA Waste Services and its 1999 financial statements.

In 1999, Cendant Corp., the travel and transportation conglomerate that owns Ramada Hotels and the Avis car rental chain, agreed to pay shareholders $2.83 billion to settle a suit alleging irregularities in its merger with CUC International Inc. The company's auditor, Ernst & Young LLP, was not fined.

Appliance maker Sunbeam Corp. was forced to restate financial results for 1996 and 1997 last May, and the SEC sued former CEO Al Dunlap (Chainsaw Al) and other executives after he was accused of using phony accounting to boost profits. The company later filed for bankruptcy. Again, Arthur Anderson was the auditor, but was not fined.

And three top executives of software firm MicroStrategy, including CEO Michael Saylor, were ordered to pay $350 million apiece for similar practices. The company and its auditor, PricewaterhouseCooopers LLC, were not fined.

Newkirk said it's important for regulators to catch the small, seemingly insignificant irregularities early on in order to prevent them from ballooning into Enron-sized situations that hurt employees and investors.

"If you fail to arrest problems when you first find them you end up in a situation of either having to go along with bigger violations in the future, or of standing up to the client and correcting it," Newkirk said. "Of course doing that involves both embarrassment to the firm and the auditor."